Cancer drug strategy flips script: PRMT1 activator boosts chemotherapy in pancreatic cancer mouse study
What if we could fight cancer by specifically activating a key enzyme instead of deactivating it? That's exactly what a research team at Marburg University has achieved for the first time with the enzyme PRMT1. The scientists developed a small molecule called TR-07 that activates PRMT1.
Researchers at Marburg University have made an intriguing discovery in the field of cancer treatment. By developing a small molecule called TR-07, which activates the enzyme PRMT1, the scientists have found a potential new approach to fighting pancreatic cancer. Traditionally, the focus has been on inhibiting PRMT enzymes implicated in cancer, but this study suggests that activating these enzymes could also be effective in certain cases.
The activation of PRMT1 led to an increase in the death of pancreatic cancer cells and enhanced the effectiveness of an established chemotherapy regimen in mouse models. This novel approach, led by researchers from various disciplines including molecular biology, medicinal chemistry, and pharmaceutical chemistry, opens up new possibilities for targeted cancer therapies.
The study, published in the Journal of Medicinal Chemistry, highlights the importance of interdisciplinary collaboration in advancing cancer research.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
